A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT03616964
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Baricitinib — DRUGAdministered orally.
- Placebo — DRUGAdministered orally
Study Details
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
Key Dates
- Start date
- Aug 2, 2018
- Status verified
- Nov 2022
- Primary completion
- Sep 24, 2021
- Completion
- Oct 20, 2021
Study Design
- Enrollment
- 778 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 2 milligram (mg) BaricitinibParticipants received one 2 mg baricitinib tablet and one placebo tablet matching 4 mg baricitinib administered orally once daily (QD) for 52 weeks.
- Experimental: 4 mg BaricitinibParticipants received one 4 mg baricitinib tablet and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
- Placebo Comparator: PlaceboParticipants received 2 placebo tablets: one placebo tablet matching 4 mg baricitinib and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
Primary Outcome Measure
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) [ Time Frame: Week 52 ]
Locations (39)
Find similar trials in Gilbert, AZ
By condition
By specialty
By research site
University of Arizona Arthritis Center· Gilbert, AZArizona Arthritis & Rheumatology Research· Phoenix, AZArizona Arthritis & Rheumatology Associates, P. C.· Tucson, AZWallace Rheumatic Studies Center· Beverly Hills, CAMedvin Clinical Research - Weidmann· Covina, CAOffice: Dr Robin K Dore· Tustin, CA
Related Studies
- Study of Systemic Lupus ErythematosusRecruiting · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Bethesda, Maryland
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)Recruiting · Hospital for Special Surgery, New York · Chicago, Illinois
- Duke Lupus RegistryRecruiting · Duke University · Durham, North Carolina
- Systemic Lupus Erythematosus in Gullah HealthRecruiting · Medical University of South Carolina · Charleston, South Carolina